GlaxoSmithKline (GSK) Limited is expected to resume its share buyback programme on Thursday despite loss due to a massive legal charge in the fourth quarter. The investors who had urged GSK to adopt ‘giving cash back’ decision of other major drug companies would greatly welcome this move.

According to Thomson Reuters estimation the giant British drugmaker is believed to reveal its forecast to record a loss of around 6 pence a share in its 2010 results.

GlaxoSmithKline's drug Benlysta has shown green signal by an advisory panel of the US Food and Drug Administration for its experimental use for the treatment of disease lupus in US.

It is for the first time in past 50 years that a medicine in the class of drugs for treating lupus has been approved. The ultimate decision on the commercialization of the drug from the FDA would come on December 9.

GlaxoSmithKline and the Brazil-based Oswald Cruz Foundation (Fiocruz) are due to carry out some effective research and come up with some new medicines for tropical diseases Chagas and leishmaniasis.

GSK's R&D hub in Tres Cantos Campus, Spain would be sued for the purpose as it is said to have its `Open Lab', concept there which had been set up in the month of January by the manufacturer.

The whole idea behind it was to enable information exchange between scientists worldwide, who are busy searching for treatments for diseases of the developing world, individually.

In 2002, pharmaceutical Company GlaxoSmithKline PLC sent Cheryl Eckard to Puerto Rico to tackle the violation problem in one of its biggest drug-making plants.

The U. S. authorities had warned that the plant is not abiding by the standards to make drugs and ointments, including one that was made to treat skin-related infections in children.

Ms. Eckard has received that the largest amount of payment or reward for whistleblowing so far in the history of the United States.

After the pharmaceutical Company GlaxoSmithKline PLC needed to reassess one of their manufacturing plants in Puerto Rico, they sent one of the Company’s quality assurance managers Cheryl Eckard. The former employee of the Company exposed severe abuses such as the production of a skin product for children that was poisonous.

Furthermore, Ms. Eckard observed that drugs often were mixed up in the same bottles in Puerto Rico, a dangerous mistake that has not been corrected.

The British pharmaceutical Company, GlaxoSmithKline has finally decided to reach a settlement regarding the numerous criminal lawsuits and civil complaints. GSK would be shelling out compensation amounting to $750million for selling contaminated baby lotion for years, despite knowing that the ointment was not fit for use.

GlaxoSmithKline has announced a new alliance with Italy-based Fondazione Telethon and Fondazione San Raffaele in order to boost its research on treatments for rare diseases.

The two Italian firms focus their work on ADA Seyer Combined Immune Deficiency, a rare genetic disorder that affects about 350 children around the world. Through the partnership GlaxoSmithKline intends to bolster its rare disease research unit. This unit will focus on diseases to which research can "realistically" make a significant contribution, says unit head Marc Dunoyer.

As a consequence of World Health Organization’s call to donate medicines in the poorest countries to wipe out tropical diseases, GlaxoSmithKline on Thursday declared to donate an additional 400 million tablets to provide treatment to children suffering with intestinal worms.

The pharmaceutical Company GlaxoSmithKline has lost yet another battle for its oncology drug Tyverb. The National Institute for Health and Clinical Excellence has in fact issued new guidelines related to the use of the drug by the NHS for the breast cancer patients it is treating.

A vaccine meant to protect women from herpes has failed to clear trials in shielding them against the virus. The declaration regarding the failure of the vaccine was made by the U. S National Institute of Health.

The manufacturer of the medicine, GlaxoSmithKline has stalled the production of the vaccination. The trials were conducted on 8,000 women from the United States and Canada. Despite administering the anti-herpes vaccine Simplirix by GSK, the women fell prey to the virus and contracted genital herpes.

A diabetes drug consumed by 100,000 Britons has been banned after complaining of the risk about the heart disease linked with it.

Avandia the drug was released to lower the blood sugar levels in case of patients having type 2 diabetes that strikes at middle and old age.

The European Medicines Agency proclaimed that the drug license has been snatched and no one can further prescribe it. Patients are advised to continue with the dosage of Avandia until another medicine is switched over.

As a result of the EMA’s decision to withdraw Avandia off the markets, GlaxoSmithKline has been experiencing losses day after day. As the market analysts gained the information regarding the fact that Avandia, the chief product of the giant pharmaceutical Company, GlaxoSmithKline, would no longer be the best selling diabetes drug in the world, they saw the fall coming.

The Food and Drug Administration unveiled the recently updated norms for the diabetes drug Avandia.

The norms can be used in case of type 2 patients and comes in form of "drug of last resort" for those patients.

Avandia which is considered to be associated with heart attacks and stroke will soon be withdrawn out of the market soon after FDA's move.

The drug will be taking the safety measures of US and health experts will be steering patients, until Avandia comes as the only left out option.

On Thursday, the European drug regulators at the European Medicines Agency (EMA) stated that the news linking Pandemrix, the H1N1 swine flu vaccine manufactured by GlaxoSmithKline, to narcolepsy was not at all true. According to the EMA, there has been no evidence that Pandemrix led to any cases of narcolepsy or any sleeping disorders, yet the investigation would still continue for duration of three to six months, in order to confirm the results. The investigations were conducted by Committee for Medicinal Products for Human Use.

The medical journal, The Lancet Oncology has reported the recent phase II clinical trial, which suggests that the drug Pazopanib or Votrient made by GlaxoSmithKline and used for the treatment of kidney cancer may also be used for the treatment of thyroid cancer.

According to the trial, a good result was observed by the researchers when 49% of the patients showed a significant response towards Pazopanib. Besides this the response lasted longer more than a year in about two third of the patients.